Literature DB >> 31864668

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.

Richard F Spaide1, Glenn J Jaffe2, David Sarraf3, K Bailey Freund4, Srinivas R Sadda3, Giovanni Staurenghi5, Nadia K Waheed6, Usha Chakravarthy7, Philip J Rosenfeld8, Frank G Holz9, Eric H Souied10, Salomon Y Cohen11, Giuseppe Querques12, Kyoko Ohno-Matsui13, David Boyer14, Alain Gaudric15, Barbara Blodi16, Caroline R Baumal6, Xiaoxin Li17, Gabriel J Coscas18, Alexander Brucker19, Lawrence Singerman20, Phil Luthert21, Steffen Schmitz-Valckenberg9, Ursula Schmidt-Erfurth22, Hans E Grossniklaus23, David J Wilson24, Robyn Guymer25, Lawrence A Yannuzzi4, Emily Y Chew26, Karl Csaky27, Jordi M Monés28, Daniel Pauleikhoff29, Ramin Tadayoni15, James Fujimoto30.   

Abstract

PURPOSE: To establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data.
DESIGN: Consensus meeting. PARTICIPANTS: An international panel of retina specialists, imaging and image reading center experts, and ocular pathologists.
METHODS: During several meetings organized under the auspices of the Macula Society, an international study group discussed and codified a set nomenclature framework for classifying the subtypes of neovascular AMD and associated lesion components. MAIN OUTCOME MEASURES: A consensus classification of neovascular AMD.
RESULTS: The study group created a standardized working definition of AMD. The components of neovascular AMD were defined and subclassified. Disease consequences of macular neovascularization were delineated.
CONCLUSIONS: The framework of a consensus nomenclature system, a definition of AMD, and a delineation of the subtypes of neovascular AMD were developed. Establishing a uniform set of definitions will facilitate comparison of diverse patient groups and different studies. The framework presented is modified and updated readily, processes that are anticipated to occur on a periodic basis. The study group suggests that the consensus standards outlined in this article be used in future reported studies of neovascular AMD and clinical practice.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31864668     DOI: 10.1016/j.ophtha.2019.11.004

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  98 in total

Review 1.  Age-related macular degeneration.

Authors:  Monika Fleckenstein; Tiarnán D L Keenan; Robyn H Guymer; Usha Chakravarthy; Steffen Schmitz-Valckenberg; Caroline C Klaver; Wai T Wong; Emily Y Chew
Journal:  Nat Rev Dis Primers       Date:  2021-05-06       Impact factor: 52.329

2.  Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

3.  Retinoid analogs and polyphenols as potential therapeutics for age-related macular degeneration.

Authors:  Tanu Parmar; Joseph T Ortega; Beata Jastrzebska
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-21

4.  Blue-light fundus autofluorescence imaging of pigment epithelial detachments.

Authors:  Almut Bindewald-Wittich; Joanna Dolar-Szczasny; Sandrine H Kuenzel; Leon von der Emde; Maximilian Pfau; Robert Rejdak; Steffen Schmitz-Valckenberg; Thomas Ach; Jens Dreyhaupt; Frank G Holz
Journal:  Eye (Lond)       Date:  2022-05-17       Impact factor: 3.775

5.  Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.

Authors:  Hamid Hosseini; Gilad Rabina; Moritz Pettenkofer; Adrian Au; Ismael Chehaibou; Gad Heilweil; Adam J Weiner; Michael Ip; Anat Loewenstein; Steven D Schwartz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-27       Impact factor: 3.117

6.  Exudative non-neovascular age-related macular degeneration.

Authors:  Tommaso Bacci; Juliet O Essilfie; Belinda C S Leong; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-26       Impact factor: 3.117

7.  Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration.

Authors:  Tiarnan D L Keenan; Usha Chakravarthy; Anat Loewenstein; Emily Y Chew; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2021-02-15       Impact factor: 5.258

Review 8.  Oxidative and Nitrosative Stress in Age-Related Macular Degeneration: A Review of Their Role in Different Stages of Disease.

Authors:  Caterina Toma; Stefano De Cillà; Aurelio Palumbo; Divya Praveen Garhwal; Elena Grossini
Journal:  Antioxidants (Basel)       Date:  2021-04-23

9.  Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24.

Authors:  Christopher K Hwang; Elvira Agrón; Amitha Domalpally; Catherine A Cukras; Wai T Wong; Emily Y Chew; Tiarnan D L Keenan
Journal:  Ophthalmol Retina       Date:  2020-10-16

10.  Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy.

Authors:  Seonghee Choi; Hae Min Kang; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-27       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.